CAMP and glioblastoma: No significant difference observed in survival in mice bearing subcutaneous GBM in response to the treatment with NE alone and NE/CAMP groups (Figure S1) can possibly be attributed to either insufficient activation of NEs by CAMPs or suboptimal dosing regimen.